Merck Wins Two U.S. Patent Reviews and German Court Lifts Ban
Merck (NYSE: MRK) secured a clean sweep in U.S. patent reviews and a German court lifted a sales ban on subcutaneous Keytruda, clearing dual commercial paths for the flagship franchise … Read More